WASHINGTON — The Food and Drug Administration has issued a long-awaited approval of Novavax ... based coronavirus vaccine – and until now it had emergency authorization from FDA for use ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...

The U.S. approved a new COVID-19 vaccine made by Moderna but with limits on who can use it — not a replacement for the company’s existing shot, but a second option.

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the FDA’s attitude toward mRNA and COVID-19 vaccines that have investors ...

The Food and Drug Administration will no longer approve COVID-19 vaccines for healthy people under 65 without rigorous trials ...

The Food and Drug Administration has approved ... Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization from FDA for ...